NDAORALTABLET
Approved
Oct 1981
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
2/8 — Basic
MODURETIC 5-50 (amiloride hydrochloride; hydrochlorothiazide) by Merck & Co.. Approved for those patients with hypertension, congestive heart failure, other kaliuretic diuretics are used alone and 3 more indications. First approved in 1981.
Drug data last refreshed 9h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
MODURETIC 5-50 is a fixed-dose combination of amiloride hydrochloride (potassium-sparing diuretic) and hydrochlorothiazide (thiazide diuretic) administered orally as a tablet. It treats hypertension and congestive heart failure by combining natriuretic and potassium-retention mechanisms to maintain electrolyte balance while reducing fluid overload. The dual mechanism addresses the kaliuretic effect of thiazides by simultaneously conserving potassium through amiloride's action.
LOE Approaching
This legacy product faces imminent loss of exclusivity, signaling a contracting team focused on managed decline and generic transition management.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications (6)
Worked on MODURETIC 5-50 at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.